BioArctic AB
BRCTF
Rank in Stocks
#4805
BioArctic AB (publ) develops biological drugs for patients with central nervous... BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Share Price
$30.33
Last synced: 2026-11-06
Market Cap
$2.84B
Change (1 day)
0.00%
Change (1 year)
9.02%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade BioArctic AB (BRCTF)
Category
Healthcare
Operating Margin for BioArctic AB (BRCTF)
Operating Margin as of November 2026 TTM: 21.37%
According to BioArctic AB's latest financial reports, its current operating margin (TTM) is 21.37%. At the end of 2025 the company had an operating margin of 68.44%.
Operating Margin history for BioArctic AB from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 21.37% | -68.78% |
| 2025 | 68.44% | -177.08% |
| 2024 | -88.79% | -316.51% |
| 2023 | 41.01% | -1,021.57% |
| 2022 | -4.45% | -99.26% |
| 2021 | -603.66% | 357.21% |
| 2020 | -132.03% | -430.57% |
| 2019 | 39.94% | -41.66% |
| 2018 | 68.46% | 399.34% |
| 2017 | 13.71% | -80.60% |
| 2016 | 70.66% | 506.52% |
| 2015 | 11.65% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -98.19% |
US
|
|
| -149.01% | -106.97% |
US
|
|
| 25.57% | -98.80% |
AU
|
|
| 31.23% | -98.54% |
BE
|
|
| 29.35% | -98.63% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BioArctic AB's operating margin
What is BioArctic AB's operating margin?
BioArctic AB's operating margin is 21.37%, as of Nov 2026.
What was BioArctic AB's operating margin in 2025?
In 2025, BioArctic AB's operating margin was 68.44%, compared with -88.79% in 2024.
How has BioArctic AB's operating margin changed since 2020?
From 2020 to 2025, BioArctic AB's operating margin was highest in 2025 (68.44%) and lowest in 2021 (-603.66%).
How does BioArctic AB's operating margin compare with similar companies?
BioArctic AB's operating margin (21.37%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.